J147
J147
J147 (/ˈdʒeɪ ˈwʌn ˈfɔːr ˈsevən/) is an experimental drug with potential therapeutic use in the treatment of Alzheimer's disease and other age-related diseases.
Etymology
The name "J147" is derived from the initials of the Salk Institute's Cellular Neurobiology Laboratory's director, Juan Carlos Izpisua Belmonte, and the number 147, which represents the 147th compound tested by the team.
Pharmacology
J147 is a modified version of a molecule found in the curry spice curcumin. It works by binding to a protein called ATP synthase, which is responsible for the production of cellular energy. By binding to ATP synthase, J147 can help to maintain the energy levels in neurons, which can become depleted in diseases like Alzheimer's.
Clinical Trials
As of 2021, J147 is in the early stages of clinical trials. The drug has shown promise in preclinical studies, with results indicating that it may not only slow the progression of Alzheimer's disease, but also reverse some of the cognitive deficits associated with the disease.
Related Terms
External links
- Medical encyclopedia article on J147
- Wikipedia's article - J147
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski